CAAS Capital Management’s HilleVax HLVX Stock Holding History

CAAS Capital Management’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15,000	Closed	-$164K	–	905
2022 Q2	$164K	Buy	+15,000	New	+$178K	0.01%	712

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's HLVX Position: Q3 2022 in Review

CAAS Capital Management sold out of HilleVax (HLVX) in Q3 2022, closing a stake of 15,000 shares — an estimated $164K sold.

CAAS Capital Management first reported a position in HLVX in Q2 2022 and held it in 1 quarter. The position peaked at $164K in Q2 2022. 51 funds tracked by Wall St. Rank hold HLVX as of Q3 2022.

CAAS Capital Management reported no remaining HilleVax position as of Q3 2022 after selling out during the quarter.
CAAS Capital Management sold 15,000 HilleVax shares in Q3 2022, an estimated $164K.
CAAS Capital Management first reported a position in HilleVax in Q2 2022 and held it in 1 quarter.
CAAS Capital Management's HilleVax position peaked at $164K in Q2 2022.
51 funds tracked by Wall St. Rank held HilleVax as of Q3 2022.

Based on CAAS Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.